Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,02 USD | -10,52% | -4,66% | +100,00% |
06/05 | CHEMOMAB THERAPEUTICS LTD. : Oppenheimer past advies aan | ZM |
10/04 | Transcript : Chemomab Therapeutics Ltd. - Special Call |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 14,5 mln. 13,43 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -16 mln. -14,81 mln. | Nettowinst (verlies) 2025 * | -21 mln. -19,44 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-2,68
x | K/w-verhouding 2025 * |
-2,76
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 4,97% |
Recentste transcriptie over Chemomab Therapeutics Ltd.
1 dag | -10,52% | ||
1 week | -4,66% | ||
Lopende maand | -4,66% | ||
1 maand | +14,77% | ||
3 maanden | +27,50% | ||
6 maanden | +112,46% | ||
Lopend jaar | +100,00% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Adi Mor
CEO | Chief Executive Officer | 43 | 22-09-11 |
Sigal Fattal
DFI | Director of Finance/CFO | 53 | 01-01-20 |
Chief Tech/Sci/R&D Officer | 56 | 14-11-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Neil Cohen
BRD | Director/Board Member | 60 | 01-04-20 |
Nissim Darvish
CHM | Chairman | 59 | 16-03-21 |
Claude Nicaise
BRD | Director/Board Member | 71 | 16-03-21 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
07-06-24 | 1,02 | -10,52% | 132 622 |
06-06-24 | 1,14 | -11,64% | 144 154 |
05-06-24 | 1,29 | +4,03% | 89 400 |
04-06-24 | 1,24 | +1,64% | 97 117 |
03-06-24 | 1,22 | +14,03% | 391 594 |
uitgestelde koers Nasdaq, 07 juni 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+100,00% | 14,5 mln. | |
+18,72% | 125 mld. | |
+14,19% | 108 mld. | |
-4,93% | 24,21 mld. | |
+3,23% | 22,78 mld. | |
-10,44% | 17,96 mld. | |
-41,74% | 16,43 mld. | |
-13,31% | 16,37 mld. | |
+2,44% | 13,58 mld. | |
+27,89% | 11,66 mld. |